Kyverna Therapeutics, Inc.

SecurityKYTX / Kyverna Therapeutics, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership449,750 shares
Latest Disclosed Value $ 3,881,342
UBS Group AG reports 122.44% increase in ownership of KYTX / Kyverna Therapeutics, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 449,750 shares of Kyverna Therapeutics, Inc. (US:KYTX) valued at $3,881,343 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 202,187 shares of Kyverna Therapeutics, Inc.. This represents a change in shares of 122.44% during the quarter. The current value of the position is $3,575,512 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F KYVERNA THERAPEUTICS COM 501976104 449,750 247,563 122.44 3,881 104.26 0.0001
2026-01-29 2025-12-31 13F KYVERNA THERAPEUTICS COM 501976104 202,187 44,765 28.44 1,901 101.27 0.0001
2025-11-13 2025-09-30 13F KYVERNA THERAPEUTICS COM 501976104 157,422 59,264 60.38 945 213.62 0.0001
2025-08-14 2025-06-30 13F KYVERNA THERAPEUTICS COM 501976104 98,158 -79,512 -44.75 301 -11.99 0.0001
2025-05-13 2025-03-31 13F KYVERNA THERAPEUTICS COM 501976104 177,670 -25,733 -12.65 343 -55.00 0.0001
2025-02-14 2024-12-31 13F KYVERNA THERAPEUTICS COM 501976104 203,403 195,207 2,381.73 761 1,800.00 0.0001
2024-11-14 2024-09-30 13F KYVERNA THERAPEUTICS COM 501976104 8,196 -1,448 -15.01 40 -44.44 0.0000
2024-08-14 2024-06-30 13F KYVERNA THERAPEUTICS COM 501976104 9,644 -15,254 -61.27 72 -88.35 0.0000
2024-05-13 2024-03-31 13F KYVERNA THERAPEUTICS COM 501976104 24,898 24,898 618 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.